{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:14Z","timestamp":1793459654051,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74481-7","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T06:03:21Z","timestamp":1730095401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors"],"prefix":"10.1038","volume":"14","author":[{"given":"Yoshihisa","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsumure","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"74481_CR1","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs, R. et al. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl. J. Med. 363, 2499\u20132510 (2010).","journal-title":"N Engl. J. Med."},{"key":"74481_CR2","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"B\u00fcller, H. R. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl. J. Med. 369, 1406\u20131415 (2013).","journal-title":"N Engl. J. Med."},{"key":"74481_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli, G. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl. J. Med. 369, 799\u2013808 (2013).","journal-title":"N Engl. J. Med."},{"key":"74481_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl. J. Med. 365, 883\u2013891 (2011).","journal-title":"N Engl. J. Med."},{"key":"74481_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano, R. P. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl. J. Med. 369, 2093\u20132104 (2013).","journal-title":"N Engl. J. Med."},{"key":"74481_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger, C. B. et al. Apixaban versus Warfarin in patients with Atrial Fibrillation. N Engl. J. Med. 365, 981\u2013992 (2011).","journal-title":"N Engl. J. Med."},{"key":"74481_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/jth.14649","volume":"18","author":"K Bunclark","year":"2020","unstructured":"Bunclark, K. et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J. Thromb. Haemost. 18, 114\u2013122 (2020).","journal-title":"J. Thromb. Haemost"},{"key":"74481_CR8","doi-asserted-by":"publisher","unstructured":"Hosokawa, K. et al.  A Multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI Trial. Circulation. 406\u2013409. https:\/\/doi.org\/10.1161\/circulationaha.123.067528 (2023).","DOI":"10.1161\/circulationaha.123.067528"},{"key":"74481_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0038-1627480","volume":"118","author":"RC Gosselin","year":"2018","unstructured":"Gosselin, R. C. et al. International Council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb. Haemost 118, 437\u2013450 (2018).","journal-title":"Thromb. Haemost"},{"key":"74481_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils, J. et al. 2021 update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb. Haemost 121, 1008\u20131020 (2021).","journal-title":"Thromb. Haemost"},{"key":"74481_CR11","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1253\/circj.CJ-15-0470","volume":"79","author":"H Osanai","year":"2015","unstructured":"Osanai, H. et al. Measurement of anti-factor Xa activity in patients on apixaban for non-valvular atrial fibrillation. Circ. J. 79, 2584\u20132590 (2015).","journal-title":"Circ. J."},{"key":"74481_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1253\/circj.CJ-15-1281","volume":"80","author":"H Osanai","year":"2016","unstructured":"Osanai, H. et al. Distribution of anti-factor Xa activity in patients on Edoxaban therapy for non-valvular atrial fibrillation. Circ. J. 80, 745\u2013747 (2016).","journal-title":"Circ. J."},{"key":"74481_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8, N. et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 37, 67\u2013119 (2016).","journal-title":"Eur. Heart J."},{"key":"74481_CR14","doi-asserted-by":"publisher","first-page":"e22869","DOI":"10.1002\/jcla.22869","volume":"33","author":"SH Park","year":"2019","unstructured":"Park, S. H. et al. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: experience at a single institution. J. Clin. Lab. Anal. 33, e22869 (2019).","journal-title":"J. Clin. Lab. Anal."},{"key":"74481_CR15","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz, S., Ahmad, D., Spyropoulos, A. C. & Schulman, S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J. Thromb. Haemost. 13, 2119\u20132126 (2015).","journal-title":"J. Thromb. Haemost"},{"key":"74481_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S. & Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692\u2013694 (2005).","journal-title":"J. Thromb. Haemost"},{"key":"74481_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman, S. et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J. Thromb. Haemost. 8, 202\u2013204 (2010).","journal-title":"J. Thromb. Haemost"},{"key":"74481_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/aje\/kwj063","volume":"163","author":"NJ Perkins","year":"2006","unstructured":"Perkins, N. J. & Schisterman, E. F. The inconsistency of \u2018optimal\u2019 cut-points using two ROC based criteria. Am. J. Epidemiol. 163, 670\u2013675 (2006).","journal-title":"Am. J. Epidemiol."},{"key":"74481_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom, J. W. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl. J. Med. 369, 1206\u20131214 (2013).","journal-title":"N Engl. J. Med."},{"key":"74481_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","volume":"6","author":"SC Woller","year":"2022","unstructured":"Woller, S. C. et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv. 6, 1661\u20131670 (2022).","journal-title":"Blood Adv."},{"key":"74481_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo, V. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 132, 1365\u20131371 (2018).","journal-title":"Blood"},{"key":"74481_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1076029616629759","volume":"22","author":"J Beyer","year":"2016","unstructured":"Beyer, J. et al. Evaluation of a heparin-calibrated antifactor Xa Assay for measuring the anticoagulant effect of oral direct xa inhibitors. Clin. Appl. Thromb. 22, 423\u2013428 (2016).","journal-title":"Clin. Appl. Thromb."},{"key":"74481_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jjcc.2016.11.013","volume":"70","author":"T Sakaguchi","year":"2017","unstructured":"Sakaguchi, T. et al. Monitoring of anti-xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J. Cardiol. 70, 244\u2013249 (2017).","journal-title":"J. Cardiol."},{"key":"74481_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40261-020-00912-8","volume":"40","author":"A Tobe","year":"2020","unstructured":"Tobe, A. et al. Comparison of anti-factor xa activity among three different factor xa inhibitors in non-valvular atrial Fibrillation patients with renal impairment. Clin. Drug Investig. 40, 567\u2013573 (2020).","journal-title":"Clin. Drug Investig"},{"key":"74481_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40268-022-00403-5","volume":"22","author":"R Ono","year":"2022","unstructured":"Ono, R. et al. Impact of renal function on anti-factor xa activity concentrations with Edoxaban Use in patients with non-valvular atrial fibrillation. Drugs R D. 22, 281\u2013288 (2022).","journal-title":"Drugs R D"},{"key":"74481_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","volume":"41","author":"M Humbert","year":"2022","unstructured":"Humbert, M. et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J. Hear. Lung Transpl. 41, 716\u2013721 (2022).","journal-title":"J. Hear. Lung Transpl."},{"key":"74481_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.thromres.2017.05.024","volume":"156","author":"L Sabor","year":"2017","unstructured":"Sabor, L., Rapha\u00ebl, M., Dogn\u00e9, J. M., Mullier, F. & Douxfils, J. Heparin-calibrated chromogenic anti-xa assays are not suitable to assess the presence of significant direct factor xa inhibitors levels. Thromb. Res. 156, 36\u201338 (2017).","journal-title":"Thromb. Res."},{"key":"74481_CR28","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","volume":"35","author":"K Parker","year":"2022","unstructured":"Parker, K. et al. A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease. J. Nephrol. 35, 2015\u20132033 (2022).","journal-title":"J. Nephrol."},{"key":"74481_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/jcph.633","volume":"56","author":"M Chang","year":"2016","unstructured":"Chang, M. et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J. Clin. Pharmacol. 56, 637\u2013645 (2016).","journal-title":"J. Clin. Pharmacol."},{"key":"74481_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","volume":"70","author":"D Kubitza","year":"2010","unstructured":"Kubitza, D. et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor xa inhibitor. Br. J. Clin. Pharmacol. 70, 703\u2013712 (2010).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"74481_CR31","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/psp4.12347","volume":"7","author":"B Cirincione","year":"2018","unstructured":"Cirincione, B. et al. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation. CPT Pharmacometr. Syst. Pharmacol. 7, 728\u2013738 (2018).","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"74481_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11239-021-02445-z","volume":"52","author":"M Porres-Aguilar","year":"2021","unstructured":"Porres-Aguilar, M. et al. Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. J. Thromb. Thrombolysis. 52, 791\u2013796 (2021).","journal-title":"J. Thromb. Thrombolysis"},{"issue":"23","key":"74481_CR33","doi-asserted-by":"publisher","first-page":"00270","DOI":"10.1016\/j.jtha.2023.03.036","volume":"S1538-7836","author":"K Hosokawa","year":"2023","unstructured":"Hosokawa, K. et al. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. J. Thromb. Haemost. S1538-7836 (23), 00270\u201300272. https:\/\/doi.org\/10.1016\/j.jtha.2023.03.036 (2023).","journal-title":"J. Thromb. Haemost"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74481-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:05:18Z","timestamp":1730369118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74481-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74481"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74481-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4893570\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"11 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshihisa Nakano reports receiving speaker and lecturer fees from Bayer, Janssen Pharmaceutical, Nippon Shinyaku, and Viatris outside the submitted work. In addition, english proofreading and article processing charges were subsidized by Adempas Post Marketing Surveillance by Bayer. Shiro Adachi reports receiving speaker and lecturer fee from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Janssen Pharmaceutical, Mochida Pharmaceutical, Nippon Shinyaku, Pfizer, and Viatris outside the submitted work. Toyoaki Murohara reports receiving speaker and lecturer fee from Bayer, Daiichi-Sankyo, and Janssen Pharmaceutical outside the submitted work. Takahisa Kondo reports receiving speaker and lecturer fee from Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Janssen Pharmaceutical, Nippon Shinyaku, and Pfizer outside the submitted work. All of the other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Human Research Ethics Committee of Nagoya University Hospital (no. 2020\u2009\u2212\u20090615).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"25762"}}